JFJennifer B. Freeman

Jennifer B. Freeman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jennifer B. Freeman has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Neurocognitive Comparison of Pediatric Obsessive-Compulsive Disorder and Trichotillomania (Hair Pulling Disorder)

    by Emily P. Wilton, Christopher A. Flessner, Elle Brennan, Yolanda Murphy, Michael Walther, Abbe Garcia, Christine Conelea, Daniel P. Dickstein, Elyse Stewart, Kristen Benito, et al.

    Obsessive-compulsive disorder (OCD) and trichotillomania (hair pulling disorder, HPD) are both considered obsessive-compulsive and related disorders due to some indications of shared etiological and phenomenological characteristics. However, a lack of direct comparisons between these disorders, especially in pediatric samples, limits our understanding of divergent versus convergent characteristics. This study compared neurocognitive functioning between children diagnosed with OCD and HPD. In total, 21 children diagnosed with HPD, 40 diagnosed with OCD, and 29 healthy controls (HCs), along with their parents, completed self−/parent-report measures and a neurocognitive assessment battery, which included tasks of inhibitory control, sustained attention, planning, working memory, visual memory, and cognitive flexibility. A series of analyses of variance (or covariance) indicated significant differences between groups on tasks examining planning and sustained attention. Specifically, children in both the OCD and HPD groups outperformed HCs on a task of planning. Further, children with OCD underperformed as compared to both the HPD and HC groups on a task of sustained attention. No between group differences were found with respect to tasks of reversal learning, working memory, spatial working memory, visual memory, or inhibitory control. The implications these findings may have for future, transdiagnostic work, as well as limitations and future directions are discussed.


  • Assessing Acute Secondary Treatment Outcomes in Early-Onset Obsessive–Compulsive Disorder

    by Mary Kathryn Cancilliere, Jennifer Freeman, Abbe Garcia, Kristen Benito, Jeffrey Sapyta, Martin Franklin

    Obsessive–compulsive disorder (OCD) in children under 8 years of age, referred to as early-onset OCD, has similar features to OCD in older children, including moderate to severe symptoms, impairment, and significant comorbidity. Family-based cognitive behavioral therapy (FB-CBT) has been found efficacious in reducing OCD symptoms and functional impairment in children ages 5–8 years with OCD; however, its effectiveness on reducing comorbid psychiatric symptoms in this same population has yet to be demonstrated. This study examined the acute effects of FB-CBT vs. family-based relaxation treatment over 14 weeks on measures of secondary treatment outcomes (non-OCD) in children with early-onset OCD. Children in the FB-CBT condition showed significant improvements from pre- to post-treatment on secondary outcomes, with a decrease in overall behavioral and emotional problems, internalizing symptoms, as well as overall anxiety symptom severity. Neither condition yielded significant change in externalizing symptoms. Clinical implications of these findings are considered.


  • Evidence Base Update of Psychosocial Treatments for Pediatric Obsessive-Compulsive Disorder: Evaluating, Improving, and Transporting What Works

    by Jennifer Freeman, Kristen Benito, Jennifer Herren, Joshua Kemp, Jenna Sung, Christopher Georgiadis, Aishvarya Arora, Michael Walther, Abbe Garcia

    Pediatric obsessive-compulsive disorder is a chronic and impairing condition that often persists into adulthood. This review refreshes the state of support for psychosocial treatments and the predictors or moderators that relate to their efficacy and evaluates how the literature has improved since the last update in 2014. A secondary goal is to propose an additional framework for the categorization of studies based on central research questions rather than treatment format. Psychosocial treatment studies conducted since the last review are described and evaluated according to methodological rigor and evidence-based classification using the Journal of Clinical Child and Adolescent Psychology evidence-based treatment evaluation criteria. Findings again converge in support of cognitive-behavioral therapy (CBT) as an effective and appropriate first-line treatment for youth with obsessive-compulsive disorder. Family-focused CBT is now well-established. A number of other treatments including CBT+ D-Cycloserine, CBT+ Sertraline, CBT+ positive family interaction therapy, and technology-based CBT are now probably efficacious. Demographic, clinical, and family factors are consistent predictors of CBT outcome with conflicting findings for neurocognitive predictors. The field has advanced significantly since the last review, but there is still room for improvement. Some of the conclusions that can be drawn may be limited by our evaluation criteria. Future directions are proposed to advance treatment outcome research beyond a focus on which treatments work to exploring factors that account for how and why they work.


  • Evidence Base Update for Psychosocial Treatments for Pediatric Obsessive-Compulsive Disorder

    by Jennifer Freeman, Abbe Garcia, Hannah Frank, Kristen Benito, Christine Conelea, Michael Walther, Julie Edmunds

    Pediatric obsessive-compulsive disorder (OCD) is a chronic and impairing condition that often persists into adulthood. Barrett, Farrell, Pina, Peris, and Piacentini (2008), in this journal, provided a detailed review of evidence-based psychosocial treatments for youth with OCD. The current review provides an evidence base update of the pediatric OCD psychosocial treatment literature with particular attention to advances in the field as well as to the methodological challenges inherent in evaluating such findings. Psychosocial treatment studies conducted since the last review are described and evaluated according to methodological rigor and evidence-based classification using the JCCAP evidence-based treatment evaluation criteria (Southam-Gerow & Prinstein, this issue). Findings from this review clearly converge in support of cognitive-behavioral therapy as an effective and appropriate first line treatment for youth with OCD (either alone or in combination with medication). Although no treatment for pediatric OCD has yet to be designated as “well-established,” both individual and individual family-based treatments have been shown to be “probably efficacious.” Moderators and predictors of treatment outcome are discussed as are the areas where we have advanced the field and the areas where we have room to grow. The methodological and clinical challenges inherent in a review of the evidence base are reviewed. Finally, future research directions are outlined.


  • The pediatric obsessive compulsive disorder treatment study for young children (POTS Jr): Developmental considerations in the rationale, design, and methods

    by Jennifer Freeman, Abbe Garcia, Kristen Benito, Christine Conelea, Jeffrey Sapyta, Muniya Khanna, John March, Martin Franklin


  • Cognitive Behavior Therapy for Pediatric Obsessive-Compulsive Disorder—Reply

    by Martin E. Franklin, Jennifer B. Freeman, John S. March

    In Reply: We concur with Mr Wang regarding the importance of examining the Pediatric OCD Treatment Study II (POTS II) trial data for potential predictors and moderators, including effects associated with psychiatric comorbidity and SRI medication. The study was a focused examination of primary outcomes; attempting to address moderation would have resulted in giving this important issue short shrift. Examination of moderators in POTS II is currently under way and will include the potential effects of comorbidity and specific SRI medication. The methodological and statistical approach taken in the POTS I moderators study1 will be closely followed. In the POTS I moderators study, findings from a comprehensive review2 served as the starting point for identifying variables shown to predict or moderate treatment outcome. These included demographic factors, severity of illness indicators, comorbidity, and family factors. Several predictors of outcome did emerge from POTS I: lower initial OCD symptom severity and impairment, better insight, fewer externalizing symptoms, and lower rates of family accommodation were associated with better response regardless of treatment assignment. However, only family history of OCD moderated outcome (ie, was specifically associated with attenuated response to a specific treatment condition).


  • Still Struggling: Characteristics of Youth With OCD Who are Partial Responders to Medication Treatment

    by J. Freeman, J. Sapyta, A. Garcia, D. Fitzgerald, M. Khanna, M. Choate-Summers, P. Moore, A. Chrisman, N. Haff, A. Naeem, et al.

    The primary aim of this paper is to examine the characteristics of a large sample of youth with OCD who are partial responders (i.e., still have clinically significant symptoms) to serotonin reuptake inhibitor (SRI) medication. The sample will be described with regard to: demographics, treatment history, OCD symptoms/severity, family history and parental psychopathology, comorbidity, and global and family functioning. The sample includes 124 youth with OCD ranging in age from 7 to 17 with a primary diagnosis of OCD and a partial response to an SRI medication. The youth are a predominantly older (age 12 and over), Caucasian, middle to upper income group who had received significant past treatment. Key findings include moderate to severe OCD symptoms, high ratings of global impairment, and significant comorbidity, despite partial response to an adequate medication trial. Considerations regarding generalizability of the sample and limitations of the study are discussed.


  • Open Access

    Behavior therapy for pediatric trichotillomania: Exploring the effects of age on treatment outcome

    by Martin E Franklin, Aubrey L Edson, Jennifer B Freeman

    A randomized controlled trial examining the efficacy of behavior therapy for pediatric trichotillomania was recently completed with 24 participants ranging in age from 7 - 17. The broad age range raised a question about whether young children, older children, and adolescents would respond similarly to intervention. In particular, it is unclear whether the younger children have the cognitive capacity to understand concepts like "urges" and whether they are able to introspect enough to be able to benefit from awareness training, which is a key aspect of behavior therapy for trichotillomania. Participants were randomly assigned to receive either behavior therapy (N = 12) or minimal attention control (N = 12), which was included to control for repeated assessments and the passage of time. Primary outcome measures were the independent evaluator-rated NIMH-Trichotillomania Severity Scale, a semi-structured interview often used in trichotillomania treatment trials, and a post-treatment clinical global impression improvement rating (CGI-I). The correlation between age and change in symptom severity for all patients treated in the trial was small and not statistically significant. A 2 (group: behavioral therapy, minimal attention control) x 2 (time: week 0, 8) x 2 (children < 9 yrs., children > 10) ANOVA with independent evaluator-rated symptom severity scores as the continuous dependent variable also detected no main effects for age or for any interactions involving age. In light of the small sample size, the mean symptom severity scores at weeks 0 and 8 for younger and older patients randomized to behavioral therapy were also plotted. Visual inspection of these data indicated that although the groups appeared to have started at similar levels of severity for children /= 10; the week 8 data show that the three younger children did at least as well as if not slightly better than the nine older children and adolescents. Behavior therapy for pediatric trichotillomania appears to be efficacious even in young children. The developmental and clinical implications of these findings will be discussed. Clinicaltrials.gov NCT00043563.


  • Open Access

    The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods

    by Jennifer B Freeman, Molly L Choate-Summers, Abbe M Garcia, Phoebe S Moore, Jeffrey J Sapyta, Muniya S Khanna, John S March, Edna B Foa, Martin E Franklin

    This paper presents the rationale, design, and methods of the Pediatric Obsessive-Compulsive Disorder Treatment Study II (POTS II), which investigates two different cognitive-behavior therapy (CBT) augmentation approaches in children and adolescents who have experienced a partial response to pharmacotherapy with a serotonin reuptake inhibitor for OCD. The two CBT approaches test a "single doctor" versus "dual doctor" model of service delivery. A specific goal was to develop and test an easily disseminated protocol whereby child psychiatrists would provide instructions in core CBT procedures recommended for pediatric OCD (e.g., hierarchy development, in vivo exposure homework) during routine medical management of OCD (I-CBT). The conventional "dual doctor" CBT protocol consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure with response prevention (EX/RP). I-CBT is a 7-session version of CBT that does not include imaginal exposure or therapist-assisted EX/RP. In this study, we compared 12 weeks of medication management (MM) provided by a study psychiatrist (MM only) with two types of CBT augmentation: (1) the dual doctor model (MM+CBT); and (2) the single doctor model (MM+I-CBT). The design balanced elements of an efficacy study (e.g., random assignment, independent ratings) with effectiveness research aims (e.g., differences in specific SRI medications, dosages, treatment providers). The study is wrapping up recruitment of 140 youth ages 7-17 with a primary diagnosis of OCD. Independent evaluators (IEs) rated participants at weeks 0,4,8, and 12 during acute treatment and at 3,6, and 12 month follow-up visits. NCT00074815.